Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYLO DUAL INTENSE vs THEALOZ in dry eye with keratitis or keratoconjunctivitis
DRKS00030214Phase 3Completed
- Sponsor
- URSAPHARM
- Start
- Sep 2022
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial in dry eye syndrome (DED), keratitis and Keratoconjunctivitis (KC) comparing HYLO DUAL INTENSE with THEALOZ (2 arms). Started Sep 2022; status: completed.
02
Drugs
ectoine + hyaluronic acidtrehalose
03
Conditions
dry eye syndrome (DED)keratitisKeratoconjunctivitis (KC)
Beyond the preview
Go deeper on DRKS00030214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00030214.